RecallRadar

FDA Device recall Z-1536-2020

Atellica CH Direct Bilirubin_2 assay In vitro Diagnostic for the determination of direct bilirubin SMN: 11097532 - Product Usage: ADVIA DBI…

On 2020-04-01 the FDA classified a Class II recall of Atellica CH Direct Bilirubin_2 assay In vitro Diagnostic for the determination of direct bilirubin SMN: 11097532 - Product Usage: ADVIA DBI… by Siemens Healthcare Diagnostics, citing bilirubin assays may exhibit a positive bias with patients on eltrombopag therapy.

Read the official FDA Device notice

AgencyFDA Device
Recall numberZ-1536-2020
ClassificationClass II
Statusterminated
Initiated2020-02-13
Published2020-04-01
Last updated2026-09-13 11:55 UTC
CompanySiemens Healthcare Diagnostics
DistributionUS

Product

Atellica CH Direct Bilirubin_2 assay In vitro Diagnostic for the determination of direct bilirubin SMN: 11097532 - Product Usage: ADVIA DBIL_ 2 is for in vitro diagnostic use in the quantitative determination of direct bilirubin in human serum and plasma on the ADVIA¿ Chemistry systems. Such measurements are useful in the screening of liver function disorders or in the diagnosis of jaundice.

Reason

Bilirubin assays may exhibit a positive bias with patients on eltrombopag therapy

Identifiers

code_info
Lot # UDI Number 190273 (01)00630414595801(10)190273(17)20201203 190187 (01)006304145…Lot # UDI Number 190273 (01)00630414595801(10)190273(17)20201203 190187 (01)00630414595801(10)190187(17)200820 190120 (01)00630414595801(10)190120(17)200521

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:55 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/device/enforcement.json?search=recall_number:%22Z-1536-2020%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.